(0.25%) 5 112.60 points
(0.25%) 38 336 points
(0.19%) 15 957 points
(-0.68%) $83.28
(2.44%) $1.970
(-0.13%) $2 344.20
(-0.10%) $27.51
(2.98%) $949.55
(-0.07%) $0.934
(-0.11%) $11.01
(-0.31%) $0.798
(1.81%) $93.54
Live Chart Being Loaded With Signals
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics...
Stats | |
---|---|
本日の出来高 | 101 565 |
平均出来高 | 93 689.00 |
時価総額 | 4.20M |
EPS | $0 ( 2024-04-03 ) |
次の収益日 | ( $0 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.210 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-27 | Scott John K Jr. | Buy | 64 289 | Series J Convertible Preffered Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 270 | Series G Redeemable Preferred Stock |
2023-11-27 | Scott John K Jr. | Sell | 2 400 | Series I Convertible Preferred Stock |
2023-11-16 | Moss Dana J | Buy | 416 667 | Common Stock |
2023-11-16 | Moss Dana J | Buy | 200 000 | Common Stock |
INSIDER POWER |
---|
99.85 |
Last 95 transactions |
Buy: 26 134 406 | Sell: 71 109 |
Navidea 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Navidea 財務諸表
Annual | 2022 |
収益: | $65 652.00 |
総利益: | $-119 295 (-181.71 %) |
EPS: | $-0.590 |
FY | 2022 |
収益: | $65 652.00 |
総利益: | $-119 295 (-181.71 %) |
EPS: | $-0.590 |
FY | 2021 |
収益: | $45 615.00 |
総利益: | $45 615.00 (100.00 %) |
EPS: | $-0.400 |
FY | 2020 |
収益: | $118 725 |
総利益: | $117 677 (99.12 %) |
EPS: | $-0.480 |
Financial Reports:
No articles found.
Navidea
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。